Adma Biologics, Inc. (NASDAQ: ADMA)

ADMA Biologics Inc is a U. S. based end to end commercial biopharmaceutical company dedicated to manufacturing marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The company focuses on immune globulin products derived from human plasma. Its operations span plasma collection fractionation purification and fill finish activities.

Revenue is derived primarily from the sale of three FDA approved immune globulin products ASCENIV BIVIGAM and Nabi HB which are used to treat primary immunodeficiency and hepatitis B exposure. The company also generates income from the sale of source plasma collected at its owned centers to third party manufacturers and from contract manufacturing and laboratory services provided to external clients. These revenue streams benefit from the company's control over both plasma supply and production processes.

The company operates through the following segments.

• The ADMA BioManufacturing segment is responsible for the fractionation purification and fill finish of immune globulin products including ASCENIV BIVIGAM and Nabi HB and for the development of pipeline candidates such as the S pneumonia hyperimmune globulin SG 001. This segment utilizes the Boca Raton Florida facility which has a peak annual processing capacity of up to six hundred thousand liters of plasma and has implemented a yield enhancement process that increases production output by twenty percent or more from the same source plasma volume. The segment also pursues label expansions for ASCENIV to include pediatric patients and conducts animal studies for SG 001 with plans to submit a pre IND package to the FDA in fiscal year 2026.

• The Plasma Collection Centers segment operates FDA licensed source plasma collection facilities that supply raw material for manufacturing and sell excess plasma to third party customers. As of year end 2025 the segment ran ten collection centers across the United States each capable of collecting thirty thousand to fifty thousand liters of source plasma annually and after a planned divestiture will retain seven centers. The segment also holds approvals from the Korean Ministry of Food and Drug Safety for certain centers and maintains authorization to run a hepatitis B immunization program.

ADMA Biologics Inc occupies a niche within the broader plasma products industry as a vertically integrated producer that controls both plasma collection and manufacturing. Its main competitors include large multinational firms such as CSL Behring Grifols Takeda Octapharma and BPL Kedrion. The company differentiates itself through proprietary donor screening methods that identify high titer plasma and through its in house fill finish capability which reduces reliance on external vendors. Recent yield enhancement initiatives and expanded four thousand four hundred liter production scales have improved gross margins and increased plant efficiency. These factors give ADMA a cost advantage and support sustained margin expansion as demand for immune globulin therapies grows.

The company sells its products to physician specialists hospitals infusion centers and specialty pharmacies through a network of national distributors and wholesalers. Major customers for the year ended 2025 were BioCare Inc and Priority Healthcare Distribution Inc doing business as CuraScript which together accounted for approximately seventy three percent of consolidated revenue. Additional revenue comes from third party plasma sales to other manufacturers and from contract service arrangements with various biopharmaceutical clients.